|Publication number||US3474777 A|
|Publication date||Oct 28, 1969|
|Filing date||Feb 10, 1966|
|Priority date||Feb 10, 1966|
|Publication number||US 3474777 A, US 3474777A, US-A-3474777, US3474777 A, US3474777A|
|Inventors||Figge Frank H J, Flower Guiles Jr|
|Original Assignee||Amp Inc|
|Export Citation||BiBTeX, EndNote, RefMan|
|Patent Citations (3), Referenced by (118), Classifications (15) |
|External Links: USPTO, USPTO Assignment, Espacenet|
Method of administering therapeutic agents
US 3474777 A
United States Patent 3,474,777 METHOD OF ADMINISTERING THERAPEUTIC AGENTS Frank H. J. Figge, Towson, Md., and Guiles Flower, In,
Carlisle, Pa., assignors to AMP Incorporated, Harrisburg, Pa., a corporation of New Jersey N0 Drawing. Filed Feb. 10, 1966, Ser. No. 526,361 Int. Cl. A6111 5/00; A6111 5/10 U.S. Cl. 128-22 13 Claims ABSTRACT OF THE DISCLOSURE Method of localizing a therapeutic agent at a preferred treatment site within an organism by injecting said agent into the organism in association with a magnetically responsive substance and concentrating the agent and substance at the preferred treatment site by the application of magnetic fields to the organism. Microcapsules and/or particles adaptable to injection and having a maximum size of five microns, said microcapsules and/ or particles comprising a therapeutic agent in association with a magnetically responsive substance.
This invention relates to methods of localizing a therapeutic agent at a preferred treatment site within an organism and to therapeutic agents for use in practising such methods.
Numerous therapeutic substances, while exerting beneficial eifects on certain portions of a diseased organism, may detrimentally aflfect other, healthy, portions of the organism. If therapeutic agents of this type are localized within the organism at those sites specifically desired to be treated with the therapeutic agent, without being dispersed generally throughout the organism, the beneficial effect of the therapeutic agent is maximized while possibly harmful elfects are minimized or eliminated.
The present invention relates to a method of localizing a threapeutic agent at a preferred treatment site within an organism by introducing said therapeutic agent into the organism in association with a magnetically responsive substance. The magnetically responsive substance and the therapeutic agent are then directed, localized, or concentrated within the organism under the influence of magnetic fields applied to the organism or to those portions of the organism to be treated. When the therapeutic agent is thus localized within the organism in association with a magnetically responsive substance, the position or location of which substance in turn is controlled by the applied magnetic field, the therapeutic agent acts locally without being generally dispersed throughout the organism. Subsequently, the therapeutic agent and associated magnetic substance can be recovered from the organism, if their continued presence is unnecessary ordetrimental, by methods discussed hereinafter. In other embodiments, the therapeutic agent and magnetic substance are dissociated within the organism, and only the magnetic substance is recovered.
By therapeutic agent herein is meant, broadly, a substance or substances having an ultimate beneficial effeet on an organism. Thus, the term as used in the present specification and claims may include materials, such. as radioactive substances, which are harmful to or destructive of living tissue. The use of such radioactive materials to destroy abnormal tissue, however, would constitute an ultimate beneficial effect to the organism and such substances are considered herein as therapeutic agents.
By a magnetically responsive substance as used in the specification and claims of this application is meant a material which responds to and/or can be directed spatially by a magnetic field or fields. The responsive substances need not be paramagnetic, although such substances are most commonly thought of as being magnetic in the conventional sense, but may also be diamagnetic. The materials may be elements or compounds, or components of compounds, and need have no particular physical form providing only that they can be influenced in their direction of movement by a magnetic field.
The association between the therapeutic agent and the magnetically responsive substance may be of diverse types. Most commonly, the agent and magnetic substance are associated together in the form of discrete particles, which particles may have the form of microcapsules. Thus, a magnetically responsive substance as understood herein may be coated with or dispersed within a therapeutic agent or, conversely, a magnetically responsive substance may be used to coat or partially coat a therapeutic agent, or as a matrix for the agent. When the particles are employed in the form of microcapsules, the magnetically responsive substance may be within the capsule shell, or the magnetic substance may form part of a shell encapsulating a therapeutic agent. In still a further embodiment, the association between the therapeutic agent and the magnetically responsive substance may be on an atomic scale, for instance where the therapeutic agent comprises a radioactive isotope prepared by irradiation or bombardment of particles of a magnetically responsive substance. In such a case, the radioactive therapeutic agent, comprising a transmuted form of the magnetically responsive substance, is dispersed atomically throughout the magnetically responsive substance. Finally, the therapeutic agent and magnetically responsive substance may be one and the same, as in the case of magnetic radioactive isotopes.
U.S. Patent 2,971,916, for example, discloses the manufacture of microscopic capsules comprising a magnetizable material. U.S. Patent 3,042,416 discloses the coating of magnetic particles of very small diameter. U.S. Patent 3,190,837 discloses methods of encapsulating various materials, specifically including solid magnetic materials.
For localization within the capillary bed of animal tissue, particles comprising a therapeutic agent and an associated magnetically responsive substance should be sufficiently small to pass freely through the capillaries. In the mouse and many other vertebrates, for example, average capillary diameter is about 78 microns, a size accommodating the red blood cells, which are about seven microns in size. Hence, for use in mice, for example, therapeutiomagnetic particles of the type contemplated by the invention would suitably have an average size of up to about 5 microns. Since about twothirds of the capillary vessels within a capillary bed are not normally engorged with blood except when circulation is stimulated by exercise, there is little chance of complete blockage of all the blood vessels of a capillary bed on introduction thereinto of particles of the type described. Also, during treatment, the particles can be moved within the capillaries by movement or rotation of the magnetic field to alter the position of the magnetically responsive particles during treatment. As will be evident to those skilled in the art, the magnetically responsive substances, and/or other inert substances having no therapeutic effect but used as coatings, to form capsule shell walls, etc. should be materials compatible with the organism, e.g. substances compatible with animal body fluids, or not forming clots when present in the blood stream of animals.
In the present invention, such microscopic particles are introduced into the organism by injection. The introduction of a therapeutic agent into the capillary bed of animal tissue is of particular importance, and may be effected either by intravenous injection or injection into an artery.
One injected into the organism, the therapeutic agent may be localized by control of the magnetically responsive substance in association therewith under the influence of applied magnetic fields. As will be evident to those skilled in the art, the magnetic fields may be established by permanent magnets, or by electromagnets, and may be altered in size, shape, and strength to adapt them to particular situations. The detection of localization of the magnetically responsive substance and associated therapeutic agent may be done by chemical analysis. Fluoroscopic or roentgenographic examination of the organism also offers a ready means of detection, since the magnetically responsive substances are commonly relatively opaque to X-rays.
Dissociation or release of a therapeutic agent from a magnetic substance is preferably initiated or promoted, if appropriate, after the therapeutic agent has been localized in an organism by magnetic direction of the magnetically responsive substance associated therewith. This dissociation may merely involve the lapse of time, as, for example, in the loss of the therapeutic properties of a radioactive isotope by partial or complete radioactive decay. Dissociation may also be effected by external agencies, such as the use of high frequency sound waves to rupture the coatings of microcapsules containing a therapuetic agent within the capsules. Most commonly, release of the therapeutic agent is effected by some agency internal to the organism. For example, a therapeutic coating on a magnetically responsive substance may simply be released with time by solution of the therapeutic agent in natural fluids of the organisms. Further, the release of a therapeutic agent from association with a magnetic substance may be initiated or speeded in response to still another substance injected or ingested into the organism after localization of the therapeutic agent in situ has been effected.
After therapeutic treatment has been completed, or the therapeutic agent and magnetically responsive substance have been dissociated, the magnetically responsive substance may be recovered from the organism if its continued presence is undesirable. For example, in an animal, magnetic fields localizing magnetic particles in particular tissues may be removed, permitting the particles to circulate in the blood stream. By passing the blood through a magnetic trap external to the organism, the particles can be localized to simplify their removal. Permitting the blood to pass through a simple T-tube connection in which one arm of the T is maintained in a magnetic field will cause magnetically responsive substances in the blood to be attracted by the magnetic field and to be retained in the arm of the tube. The substances are thus isolated from the blood of the animal.
The methods of the present invention can be utilized for the administration of local anesthesia, for example, both within tissues generally or in the spinal fluid of a vertebrate. Endocrine glands can be stimulated or inhibited by the administration of drugs or other endocrine substances whose effects are localized in the glands. Cortisone or cortisone-like substances, for example, can be administered directly to rheumatic joints while minimizing side effects such as ulcers, edema, and endocrine upset associated with general dispersal of cortisone through an animal organism. Abnormal or cancerous tissue can also be treated.
Such abnormal tissue can presently be destroyed, or the cells thereof rendered incapable of further reproduction, by a variety of compounds known to the art, including materials such as 6-mercaptopurine, buslfan, chlorambucil, methotrexate, nitrogen mustards, azetepa, fluorouracil, or 5-fluoro-deoxyuridine. Compounds of this type,
although highly effective in destroying unwanted tissue, also attack tissue in other portions 'of the organism since they must, in the present state of the art, be introduced into the blood stream and dispersed generally throughout the organism. -In many cases, the maximum dose of such a therapuetic agent which can be administered is determined solely by the maximum detrimental effect which can be tolerated by portions of the organism other than that being treated. Using the methods of the present invention, the severe side effects of these drugs on healthy tissue can be minimized without loss of effect on abnormal tissue being treated.
What is claimed is:
1. The method of localizing a therapeutic agent at a preferred treatment site within an organism which comprises injecting said agent into said organism in association with a magnetically responsive substance and concentrating said agent and substance at said preferred treatment site by the application of magnetic fields to said organism.
2. The method as in claim 1 wherein said therapeutic agent and associated magnetically responsive substance are associated in a plurality of microscopic particles.
3. The method as in claim 2 wherein said microscopic particles comprise microcapsules.
4. The method as in claim 1 wherein said magnetically responsive substance is said therapeutic agent.
5. The method as in claim 1 wherein said therapeutic agent and associated magnetically responsive substance dissociate with time.
6. The method as in claim 1 wherein said therapeutic agent and associated magnetically responsive substance dissociate in response to an agency external to said organism.
7. The method as in claim 1 wheren said therapeutic agent and associated magnetically responsive substance dissociate in response to an agency within said organism.
8. The method as in claim 1 wherein said therapeutic agent comprises a radioactive isotope.
9. The method as in claim 1 wherein said therapeutic agent comprises a substance antagonistic to abnormal cell growth.
10. Microcapsules adaptable to injection and having a maximum particle size of about five microns, said microcapsules comprising a therapeutic agent in association with a magneticaly responsive substance.
11. Finely-divided particles of a magnetically responsive substance having a coating of a therapeutic agent thereon, said particles being adaptable to injection and having a maximum particle size of about five microns.
12. Microcapsules as in claim 10 wherein said therapeutic agent comprises a substance antagonistic to abnormal cell growth.
13. Particles as in claim 11 wherein said therapeutic agent is a substance antagonistic to abnormal cell growth.
References Cited UNITED STATES PATENTS 2,671,451 3/1954 Bolger 12826O 3,057,344 10/1962 Abella et a1. 128-2 3,159,545 12/1964 Kidwell et al. 16751 X OTHER REFERENCES Injection Gun: Cancer treatment tester, Washington Post, Feb. 1, 1968.
ADELE M. EAGER, Primary Examiner US. Cl. X.R.
|Cited Patent||Filing date||Publication date||Applicant||Title|
|US2671451 *||Jun 16, 1952||Mar 9, 1954||Bolger Stephen J||Remedial pill|
|US3057344 *||May 21, 1957||Oct 9, 1962||Alberto Abella Carlos||Capsule for the study of the digestive tract and method of using the same|
|US3159545 *||Oct 4, 1960||Dec 1, 1964||Abbott Lab||Radioactive capsules|
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US4247406 *||Apr 23, 1979||Jan 27, 1981||Widder Kenneth J||Intravascularly-administrable, magnetically-localizable biodegradable carrier|
|US4303636 *||May 12, 1978||Dec 1, 1981||Gordon Robert T||Cancer treatment|
|US4323056 *||May 19, 1980||Apr 6, 1982||Corning Glass Works||Radio frequency induced hyperthermia for tumor therapy|
|US4331654 *||Jun 13, 1980||May 25, 1982||Eli Lilly And Company||Drug carrier formulation|
|US4345588 *||Jun 27, 1980||Aug 24, 1982||Northwestern University||Method of delivering a therapeutic agent to a target capillary bed|
|US4357259 *||Dec 12, 1977||Nov 2, 1982||Northwestern University||Method of incorporating water-soluble heat-sensitive therapeutic agents in albumin microspheres|
|US4359453 *||Apr 7, 1978||Nov 16, 1982||Gordon Robert T||Atherosclerosis treatment method|
|US4590922 *||Aug 19, 1983||May 27, 1986||Gordon Robert T||Use of ferromagnetic, paramagnetic and diamagnetic particles in the treatment of infectious diseases|
|US4622952 *||Dec 14, 1984||Nov 18, 1986||Gordon Robert T||Cancer treatment method|
|US4657543 *||Jul 23, 1984||Apr 14, 1987||Massachusetts Institute Of Technology||Ultrasonically modulated polymeric devices for delivering compositions|
|US4690130 *||Dec 19, 1985||Sep 1, 1987||Mirell Stuart G||Localization of chemotherapy within body by associating agent with magnetic material having hihg curie temperature|
|US4690682 *||Jan 14, 1986||Sep 1, 1987||Damon Biotech, Inc.||Semipermeable microcapsules|
|US4731239 *||Oct 7, 1986||Mar 15, 1988||Gordon Robert T||Method for enhancing NMR imaging; and diagnostic use|
|US4764359 *||Dec 16, 1985||Aug 16, 1988||Lemelson Jerome H||Drug compositions and their use in treating human or other mammalian patients|
|US4770183 *||Jul 3, 1986||Sep 13, 1988||Advanced Magnetics Incorporated||In vivo diagnosis, iron oxides coated with protein or carbohydrate|
|US4779806 *||Nov 28, 1986||Oct 25, 1988||Massachusetts Institute Of Technology||Encapsulation bioactive material in polymer matrix; releasing by applying ultrasonic waves|
|US4789516 *||May 14, 1987||Dec 6, 1988||Damon Biotech, Inc||Microencapsulation; reservoir of substance in one or more capsules|
|US4814098 *||Aug 28, 1987||Mar 21, 1989||Bellex Corporation||Magnetic material-physiologically active substance conjugate|
|US4889707 *||Jan 29, 1988||Dec 26, 1989||The Curators Of The University Of Missouri||Composition and method for radiation synovectomy of arthritic joints|
|US4983159 *||Sep 17, 1986||Jan 8, 1991||Rand Robert W||Injecting ferromagnetic particles near tumor site, subjecting to alternating magnetic field|
|US5079006 *||Jul 13, 1988||Jan 7, 1992||Aprex Corporation||Pharmaceutical compositions containing a magnetically detectable material|
|US5125888 *||Jan 10, 1990||Jun 30, 1992||University Of Virginia Alumni Patents Foundation||Magnetic stereotactic system for treatment delivery|
|US5129877 *||Sep 14, 1990||Jul 14, 1992||University Of Georgia Research Foundation, Inc.||Receptor-mediated delivery system|
|US5171215 *||Aug 22, 1991||Dec 15, 1992||Flanagan Dennis F||For promoting the transfer of medicine through the skin via injection|
|US5401516 *||Apr 22, 1993||Mar 28, 1995||Emisphere Technologies, Inc.||Encapsulation of biologically active materials, drug delivery, reaction with benzenesulfonyl chloride or benzoyl chloride|
|US5443841 *||Jul 27, 1992||Aug 22, 1995||Emisphere Technologies, Inc.||Proteinoid microspheres and methods for preparation and use thereof|
|US5447728 *||Dec 16, 1993||Sep 5, 1995||Emisphere Technologies, Inc.||A carrier comprising an acylated amino acid; lowering iron concentration in mammals|
|US5458597 *||Nov 8, 1993||Oct 17, 1995||Zomed International||For delivering chemotherapeutic agents in a tissue treatment site|
|US5472441 *||Mar 11, 1994||Dec 5, 1995||Zomed International||Device for treating cancer and non-malignant tumors and methods|
|US5486161 *||Nov 8, 1993||Jan 23, 1996||Zomed International||Medical probe device and method|
|US5529568 *||Mar 18, 1994||Jun 25, 1996||Surgery Futures Research, Inc.||Magnetic operating table|
|US5540939 *||Apr 25, 1994||Jul 30, 1996||Emisphere Technologies, Inc.||Encapsulating active materials|
|US5541155 *||Apr 22, 1994||Jul 30, 1996||Emisphere Technologies, Inc.||Acids and acid salts and their use in delivery systems|
|US5578323 *||Jun 14, 1993||Nov 26, 1996||Emisphere Technologies, Inc.||Proteinoid carriers and methods for preparation and use thereof|
|US5593379 *||Jun 5, 1995||Jan 14, 1997||Surgery Futures Research, Inc.||For carrying out laparoscopic surgery of an intestine|
|US5601846 *||May 9, 1995||Feb 11, 1997||Emisphere Technologies, Inc.||Oligopeptide|
|US5629020 *||Apr 22, 1994||May 13, 1997||Emisphere Technologies, Inc.||Delivery of sensitive agents such as bioactive peptides|
|US5643957 *||Oct 25, 1994||Jul 1, 1997||Emisphere Technologies, Inc.||Compounds and compositions for delivering active agents|
|US5650386 *||Mar 31, 1995||Jul 22, 1997||Emisphere Technologies, Inc.||Compositions for oral delivery of active agents|
|US5667806 *||Jun 7, 1995||Sep 16, 1997||Emisphere Technologies, Inc.||Spray drying method and apparatus|
|US5693338 *||Sep 29, 1994||Dec 2, 1997||Emisphere Technologies, Inc.||Delivery composition comprising active agent, diketopiperazine, enzyme inhibitor|
|US5709861 *||Jan 13, 1995||Jan 20, 1998||Emisphere Technologies, Inc.||Compositions for the delivery of antigens|
|US5714167 *||Oct 25, 1994||Feb 3, 1998||Emisphere Technologies, Inc.||Reversibly forming supramolecular complex of active agent with perturbant; drug delivery|
|US5750147 *||Jun 7, 1995||May 12, 1998||Emisphere Technologies, Inc.||Fungicides for oral administration|
|US5766633 *||Apr 22, 1994||Jun 16, 1998||Emisphere Technologies, Inc.||Modified amino acid carrier, bioactive peptides|
|US5779694 *||Jul 19, 1993||Jul 14, 1998||The University Of Virginia Alumni Patents Foundation||Drug delivery apparatus|
|US5792451 *||Mar 2, 1994||Aug 11, 1998||Emisphere Technologies, Inc.||Oral drug delivery compositions and methods|
|US5804688 *||Feb 7, 1997||Sep 8, 1998||Emisphere Technologies, Inc.||Compounds and compositions for delivering active agents|
|US5811127 *||Oct 24, 1994||Sep 22, 1998||Emisphere Technologies, Inc.||Desferrioxamine oral delivery system|
|US5811128 *||Sep 7, 1993||Sep 22, 1998||Southern Research Institute||Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor|
|US5814344 *||Jun 6, 1995||Sep 29, 1998||Southern Research Institute||Method for delivering bioactive agents into and through the mucosally associated lymphoid tissues and controlling their release|
|US5820881 *||Apr 28, 1995||Oct 13, 1998||Emisphere Technologies, Inc.||Microspheres of diamide-dicarboxylic acids|
|US5820883 *||Jun 6, 1995||Oct 13, 1998||Southern Research Institute||Administering two separately microencapsulated active agents; first agent causes primary immune response, second agent is released in pulsating manner to potentiate response|
|US5824345 *||Jun 7, 1995||Oct 20, 1998||Emisphere Technologies, Inc.||Microsphere comprising active agent, proteinoid, modified hydrolyzed vegetable protein|
|US5840340 *||Aug 30, 1996||Nov 24, 1998||Emisphere Technologies, Inc.||Oligopeptides with fragrance, cosmetics and dye|
|US5853763 *||Jun 6, 1995||Dec 29, 1998||Southern Research Institute||Method for delivering bioactive agents into and through the mucosally-associated lymphoid tissue and controlling their release|
|US5863944 *||Apr 30, 1997||Jan 26, 1999||Emisphere Technologies, Inc.||Compounds and compositions for delivering active agents|
|US5866536 *||Feb 6, 1997||Feb 2, 1999||Emisphere Technologies, Inc.||Compounds and compositions for delivering active agents|
|US5876710 *||Feb 7, 1997||Mar 2, 1999||Emisphere Technologies Inc.||Drug delivery; using a brominated benzamide compound|
|US5879681 *||Feb 7, 1997||Mar 9, 1999||Emisphere Technolgies Inc.||Compounds and compositions for delivering active agents|
|US5913855 *||Nov 3, 1997||Jun 22, 1999||Rita Medical Systems, Inc.||Multiple antenna ablation apparatus and method|
|US5925042 *||Nov 3, 1997||Jul 20, 1999||Rita Medical Systems, Inc.||Multiple antenna ablation apparatus and method|
|US5928229 *||Oct 30, 1997||Jul 27, 1999||Rita Medical Systems, Inc.||Tumor ablation apparatus|
|US5939381 *||Feb 7, 1997||Aug 17, 1999||Emisphere Technologies, Inc.||4-(4-(phenoxyacetyl)aminophenyl)butyric acid as a carrier for drug delivery|
|US5942252 *||Jun 6, 1995||Aug 24, 1999||Southern Research Institute||Increasing the bioavailability of a drug by administering an effective amount of microcapsules to animal, the microcapsules comprising active agent encapsulated in a biocompatible and biodegradable excipient|
|US5951547 *||Nov 3, 1997||Sep 14, 1999||Rita Medical Systems, Inc.||Multiple antenna ablation apparatus and method|
|US5955503 *||Feb 6, 1997||Sep 21, 1999||Emisphere Technologies, Inc.||Modified amino acid compounds useful as carriers in the delivery of biologically active agents such as, for example, bioactive peptides and the like|
|US5958457 *||May 10, 1995||Sep 28, 1999||Emisphere Technologies, Inc.||Compositions for the delivery of antigens|
|US5962710 *||May 9, 1997||Oct 5, 1999||Emisphere Technologies, Inc.||Reacting an oligosalicylate and an amino acid|
|US5965121 *||Feb 6, 1997||Oct 12, 1999||Emisphere Technologies, Inc.||Compounds and compositions for delivering active agents|
|US5972387 *||Nov 21, 1994||Oct 26, 1999||Emisphere Technologies, Inc.||Modified hydrolyzed vegetable protein microspheres and methods for preparation and use thereof|
|US5976569 *||Apr 29, 1997||Nov 2, 1999||Emisphere Technologies, Inc.||Diketopiperazine-based delivery systems|
|US5980517 *||Mar 25, 1998||Nov 9, 1999||Rita Medical Systems, Inc.||Cell necrosis apparatus|
|US5989539 *||Feb 6, 1997||Nov 23, 1999||Emisphere Technologies, Inc.||Compounds and compositions for delivering active agents|
|US5990166 *||Feb 7, 1997||Nov 23, 1999||Emisphere Technologies, Inc.||Compounds and compositions for delivering active agents|
|US6001347 *||Feb 6, 1997||Dec 14, 1999||Emisphere Technologies, Inc.||Organic acid compound of given structure having an aromatic amide group, a methoxy group in the ortho position on the aromatic ring, and a lipophilic chain terminated with a carboxylic acid is useful as a nontoxic carrier|
|US6024983 *||Sep 7, 1993||Feb 15, 2000||Southern Research Institute||Potentiating immunology biocompatible excipients in microcapsules|
|US6051258 *||Jun 7, 1995||Apr 18, 2000||Emisphere Technologies, Inc.||Proteinoid emulsions and methods for preparation and use thereof|
|US6059780 *||Nov 4, 1997||May 9, 2000||Rita Medical Systems, Inc.||Multiple antenna ablation apparatus and method with cooling element|
|US6060513 *||Feb 7, 1997||May 9, 2000||Emisphere Technologies, Inc.||Compounds and compositions for delivering active agents|
|US6071280 *||Feb 14, 1997||Jun 6, 2000||Rita Medical Systems, Inc.||Multiple electrode ablation apparatus|
|US6071510 *||Apr 23, 1997||Jun 6, 2000||Emisphere Technologies, Inc.||Modified amino acids and compositions comprising the same for delivering active agents|
|US6071538 *||Sep 30, 1997||Jun 6, 2000||Emisphere Technologies, Inc.||Oral delivery composition comprising supramolecular complex|
|US6080150 *||Feb 24, 1998||Jun 27, 2000||Rita Medical Systems, Inc.||Cell necrosis apparatus|
|US6084112 *||Sep 10, 1996||Jul 4, 2000||Emisphere Technologies, Inc.||Method for preparing ω-aminoalkanoic acid derivatives from cycloalkanones|
|US6090105 *||Nov 17, 1997||Jul 18, 2000||Rita Medical Systems, Inc.||Multiple electrode ablation apparatus and method|
|US6090958 *||Feb 7, 1997||Jul 18, 2000||Emisphere Technologies, Inc.||N-(8-carboxyoctyl)-o-hydroxybenzamide and salts|
|US6099856 *||Dec 10, 1996||Aug 8, 2000||Emisphere Technologies, Inc.||Increased bioavailable|
|US6100285 *||Nov 11, 1997||Aug 8, 2000||Emisphere Technologies, Inc.||Method of solubilizing itraconazole|
|US6100298 *||Feb 6, 1997||Aug 8, 2000||Emisphere Technologies, Inc.||Mixture of drug and n-(4-(carboxypropyl)phenyl-4-phenyl-butyramide for improved oral drug delivery|
|US6132425 *||Feb 6, 1998||Oct 17, 2000||Gough; Edward J.||Cell necrosis apparatus|
|US6180140||Jun 2, 1995||Jan 30, 2001||Emisphere Technologies, Inc.||Modified amino acids for drug delivery|
|US6216030||Jul 13, 1998||Apr 10, 2001||The University Of Virginia Alumni Patents Foundation||Magnetic stereotactic system for treatment delivery|
|US6221367||Sep 29, 1997||Apr 24, 2001||Emisphere Technologies, Inc.||Exposing a biologically active agent to a complexing perturbant to reversibly transform the biologically active agent to the intermediate state and to form a transportable supramolecular complex|
|US6242495||Jun 16, 2000||Jun 5, 2001||Emisphere Technologies, Inc.||Compounds and compositions for delivering active agents|
|US6245359||Sep 30, 1997||Jun 12, 2001||Emisphere Technologies, Inc.||Active agent transport systems|
|US6313088||Feb 7, 1997||Nov 6, 2001||Emisphere Technologies, Inc.||Carriers used to deliver various active agents through various biological, chemical, and physical barriers|
|US6331318||Sep 30, 1994||Dec 18, 2001||Emisphere Technologies Inc.||Carbon-substituted diketopiperazine delivery systems|
|US6346242||Feb 8, 2000||Feb 12, 2002||Emishpere Technologies, Inc.||Compounds and compositions for delivering active agents|
|US6348207||Sep 30, 1997||Feb 19, 2002||Emisiphere Technologies, Inc.||Exposing biologically active agent to complexing perturbant to reversibly transform biologically active agent to intermediate state and form orally deliverable supramolecular complex, orally administering complex to subject|
|US6375983||Jun 12, 1997||Apr 23, 2002||Emisphere Technologies, Inc.||Microencapsulated fragrances and method for preparation|
|US6413550||Nov 23, 1998||Jul 2, 2002||Emisphere Technologies, Inc.||Proteinoid carriers and methods for preparation and use thereof|
|US6428780||May 5, 1999||Aug 6, 2002||Emisphere Technologies, Inc.||Modified amino acid|
|US6461545||Jan 6, 2000||Oct 8, 2002||Emisphere Technologies, Inc.||Method of solubilizing and encapsulating itraconazole|
|US6958062||Nov 3, 1997||Oct 25, 2005||Rita Medical Systems, Inc.||Multiple antenna ablation apparatus and method|
|US7417022||Apr 11, 2005||Aug 26, 2008||Mhr Institutional Partners Iia Lp||Amino acid for deliverying active materials; bioavailability|
|US7553872||Feb 13, 2006||Jun 30, 2009||Emisphere Technologies, Inc.||Compounds and compositions for delivering active agents|
|US7846201 *||Oct 14, 2005||Dec 7, 2010||The Children's Hospital Of Philadelphia||matrix-forming agent; a polyelectrolyte-amphiphilic agent adduct formed by an ionic association of a polyelectrolyte with a first amphiphilic agent and having a C4-C24 hydrocarbon chain, is in physical communication with the matrix-forming polymer, a coated magnetic field-responsive agent and biomaterial|
|US8562505||May 1, 2008||Oct 22, 2013||The Children's Hospital Of Philadelphia||Uniform field magnetization and targeting of therapeutic formulations|
|US8686154||Jun 10, 2009||Apr 1, 2014||Emisphere Technologies, Inc.||Compounds and compositions for delivering active agents|
|US8734439||Mar 4, 2008||May 27, 2014||Angiodynamics, Inc||Ablation apparatus and method|
|US20100241058 *||Mar 18, 2010||Sep 23, 2010||Ahmed Syed Yosuf||Oct guided tissue ablation|
|USRE35862 *||Aug 14, 1987||Jul 28, 1998||Emisphere Technologies, Inc.||Delivery systems for pharmacological agents encapsulated with proteinoids|
|DE2828941A1 *||Jun 30, 1978||Jan 10, 1980||Robert Thomas Gordon||Mittel zur behandlung von krebs|
|EP0000667A1 *||Jul 28, 1978||Feb 7, 1979||Northwestern University||Intravascularly-administrable, magnetically-localizable biodegradable carrier and process for its preparation|
|EP0042249A2||Jun 10, 1981||Dec 23, 1981||Northwestern University||Magnetically-localizable, biodegradable lipid microspheres|
|WO1982002339A1 *||Jan 7, 1982||Jul 22, 1982||Robert W Rand||Induction heating method and apparatus for use in causing necrosis of neoplasm|
|WO1987003798A1 *||Dec 2, 1986||Jul 2, 1987||Stuart G Mirell||Electromagnetic therapy control system|
| || |
|U.S. Classification||424/1.29, 604/36, 600/407, 424/489, 600/2, 424/9.4, 424/1.33, 600/12, 424/1.37, 604/28|
|International Classification||A61N2/10, A61N2/00, A61K9/50|